News Column

U.S. Department of Defense Recommends Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections for...

May 13, 2014

U.S. Department of Defense Recommends Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections for Funding

Neumedicines Inc., a privately held biotechnology company, announced that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

According to a release, Neumedicines' proposal, "Recombinant Interleukin-12, a Broad-Spectrum Biologic for the Treatment of Battle and Traumatic Wound Infections," was submitted in response to the Fiscal Year 2014 (FY14) Defense Medical Research and Development Program (DMRDP) Military Infectious Diseases Clinical Trial Award (MID-CTA), which is solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA).

Neumedicines reported that Interleukin-12 (IL-12) plays a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity while also playing a critical role in hematopoietic cell-to-cell signaling. IL-12's role in cell-to- cell signaling of other adult stem cell populations, including those found in skin, is being investigated.

"We are extremely grateful for the DoD's funding recommendation, encouraged by the response of their scientific review, and excited about the scientific and clinical implications of this R&D. rHuIL- 12 has great promise as a treatment for wound healing and infection," said Dr. Lena Basile, Neumedicines Founder and Chief Executive Officer.

Further, under the trade name HemaMax, Neumedicines is also developing rHuIL-12 as a treatment for the hematopoietic syndrome of acute radiation syndrome (HSARS) and as a treatment for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.

HemaMax (rHuIL-12) holds considerable value and promise playing a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity while also playing a critical role in hematopoietic cell-to-cell signaling. In addition to HSARS, HemaMax is also being developed for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.

The Defense Medical Research and Development Program (DMRDP) is a core research program of the Department of Defense (DoD) within the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]).

More information:

www.neumedicines.com

cdmrp.army.mil/dmrdp/

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Professional Services Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters